EPIGEN

Medical Devices & EquipmentSeedHeungdeok-gu,, South Koreaepigen.kr

Latest round

Seed

Last raised

Feb 2023

Total raised

Undisclosed

Investors

1

About EPIGEN

Founded in 2021, and based in Chungcheongbuk-do, South Korea, EPIGEN operates as a medical device manufacturing company that provides its clients with laboratory equipment for professional research. Financial terms of the deal were not disclosed. EPIGEN offers its clients with laboratory equipment for professional research including microscopes, testing kit systems, and reagent for research.

Who invested in EPIGEN

1 investor across 1 round

See all investors in EPIGEN

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Seed

    Feb 28, 2023

    Amount

    Undisclosed

    Investors

    Locked

Questions about EPIGEN

Who invested in EPIGEN?

EPIGEN has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has EPIGEN raised?

EPIGEN has raised 1 venture round. Sign up free to see how much each round raised and the total.

When did EPIGEN last raise money?

EPIGEN's most recent round on record is a Seed, in Feb 2023.

What does EPIGEN do?

Founded in 2021, and based in Chungcheongbuk-do, South Korea, EPIGEN operates as a medical device manufacturing company that provides its clients with laboratory equipment for professional research.

Where is EPIGEN headquartered?

EPIGEN is headquartered in Heungdeok-gu,, South Korea.

Which VCs invest in companies like EPIGEN?

Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back medical devices & equipment companies at EPIGEN's stage. Their profiles are linked below.

Raising like EPIGEN? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.